Phase 2 N=48 Influenza A 2009 H1N1 Challenge Study in Healthy Adults
Influenza
Primary: Percent MMID — 0; 0; 20; 47 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=74 Evaluation of Anti-Hemagglutinin (Anti-HA) Antibodies as Protection From the Flu in Healthy People
Influenza
Primary: Number of Patients With Mild to Moderate Influenza Disease (MMID) — 6; 29 participants
Phase 1 N=50 Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults
Influenza
Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each HA-F A/Sing Product Administration — 4; 3; 7; 9 Participants
Phase 1 N=52 Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults
Influenza Infection
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each H1ssF_3928 Product Administration — 5; 8; 11; 9 Participants
Phase 1 N=25 Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults
Influenza
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each H10ssF-6473 Product Administration — 3; 9; 5; 17 Participants
Phase 2 N=145 Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model
Influenza
Primary: Degree of Nasopharyngeal Viral Shedding as Determined by Quantitative Polymerase Chain Reaction qPCR — 649.7; 726.1; 646.5; 726.1 hour*Log10 Viral Particles/ ml — p=0.1711
Phase 1 N=60 Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain
Influenza
Primary: Number and Percentage of Participants With Symptomatic Influenza Virus Infection After Challenge. — 4; 5; 28; 0 Participants
Phase 2 N=91 Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Volunteer Human Challenge Model
H1N1 Influenza Healthy Volunteers
Primary: Area Under the Curve (AUC) of Viral Shedding — 48.56; 25.53 ViralLoad(log(copies/ml))per time(hours) — p=0.31
N/A N=33 Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain
Influenza A H3N2
Primary: Occurrence of Adverse Events Related to the Viral Challenge — 0; 0; 1; 6 Occurrence of adverse events
Phase 2 N=175 A Randomised, Double-blind, Placebo-controlled Phase IIb Trial to Test FLU-v Vaccine
Influenza
Primary: CD4+ and CD8+ Th1 Cellular Immunogenicity on Day 42 — 0.5; 5.9; 1.0; 0.2 fold change — p=0.45
Phase 1 N=45 Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine
Influenza
Primary: Safety - Serious Adverse Event — 0; 0; 0 SAEs
Phase 1 N=63 First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults
Influenza · Seasonal Influenza
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Product Administration — 4; 12; 9; 8 Participants
Phase 1 N=76 H1N1v Virus Challenge Study in Healthy Subjects
Influenza
Primary: Percentage of Healthy Participants Reporting Mild-to-Moderate Influenza Disease (MMID) by Baseline A/Bethesda/MM2/H1N1 Hemagglutination Inhibition (HAI) Antibody…
Phase 3 N=64 Zanamivir Versus Trivalent Split Virus Influenza Vaccine
Influenza
Primary: Number of Laboratory Confirmed Influenza Infections — 2; 1 infections — p=0.25
Phase 2 N=62 Study of SAB-176 in Healthy Adult Participants
Influenza A H1N1
Primary: To Evaluate Viral Load by Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR) of SAB-176 When Compared to Placebo — 273.05; 91.98 Log10 copies*hour/mL
Phase 2 N=98 Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine
Healthy Volunteer
Primary: Microneutralization Titers — 0.769; 1.313; 1.716; 1.333 Log2 Fold Change
Phase 1 N=241 Flublok or Fluzone With Advax-CpG55.2 or AF03
Influenza · Influenza Immunisation
Primary: Number of Participants Reporting Local and Systemic Solicited Reactogenicity Events Post First Vaccination — 24; 25; 23; 23 Participants
Phase 4 N=20 Immune Response Following Seasonal Influenza Vaccination
Influenza
Primary: HAI Antibody Immune Response to Matched Influenza Strain H1N1 A/California/04/2009 Strain — 293.4 Geometric Mean Titer
Phase 2 N=153 Efficacy of FLU-v in an H1N1 Influenza Human Challenge Model
Influenza
Primary: Number of Participants With Mild to Moderate Influenza Disease (MMID) — 23; 13; 15; 19 Participants — p=0.03
Phase 1 N=60 A Study of a Seasonal Trivalent Split, Inactivated Influenza Vaccine
Influenza, Human
Primary: Number of Subjects With Immediate Adverse Events — 0; 0 Participants
Phase 1 N=35 Single Ascending Dose Challenge Study to Determine Safety and Reactogenicity of an Influenza Challenge Virus
Influenza
Primary: Viral Shedding — 8; 4; 7; 4 Participants
Phase 1 N=27 Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants
Influenza Type A · Influenza Type B · Influenza
Primary: Number of Participants Having Adverse Events — 0; 1; 1; 1 Participants
Phase 4 N=38 Live Attenuated Influenza Vaccine (LAIV) Versus Trivalent Inactivated Influenza Vaccine in Healthy Adults 18-49 Years
Influenza
Primary: Serum Antibody Responses — 11.76; 11.11; 47.03; 9.33 Titers — p=0.89
Phase 3 N=1,561 Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects
Prophylaxis: Influenza
Primary: Immunologic Equivalence of 3 Consecutive Influenza Vaccine (TIVc) Production Lots. — 667; 738; 655; 466 Titers
Phase 2 N=43 Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant
Influenza
Primary: Flu Antibody Titers — 10.65; 10.35; 31.09; 10.35 Titers
Phase 1 N=60 Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S)
Influenza, Human
Primary: Number of Participants With Immediate Adverse Events — 0; 0 participants
Phase 2 N=179 A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine
Influenza
Primary: Number of Subjects With Influenza-like Clinical Illness and Laboratory Confirmed Infection Post Challenge With a Homologous A Strain Influenza Virus — 17; 19; 15…
N/A N=66 Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly
Influenza
Primary: Efficacy, Measured by the Number of Subjects With a Change in Innate Immune Signatures — 22; 44 participants
Phase 4 N=303 A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
Influenza
Primary: Percentage of Participants Reporting Fever Within 7 Days Post Vaccination — 0.0; 1.7 Percentage of Participants
Phase 2 N=30 H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses
Avian Influenza · H1N1 Influenza · Influenza
Primary: Percentage of Participants Achieving Seroconversion Based on HAI Titer (A/H7N9 Vaccine, With and Without Adjuvant) — 80.0; 0 percentage of participants